Cardiovascular Drugs and Therapy

, Volume 4, Supplement 4, pp 853–859 | Cite as

Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study

  • Sergio Dalla-Volta
  • Giuseppe Maraglino
  • Patricia Della-Valentina
  • Pietro Viena
  • Alessandro Desideri
Poster Presentations


Trimetazidine has been shown to have an antianginal effect, increasing exercise capability without producing any significant change of heart rate or systolic blood pressure. The aim of this study was to compare trimetazidine efficiency to that of another classical antianginal drug. A double-blind crossover trimetazidine versus nifedipine trial was carried out in 39 male patients, mean age 58 years, with effort angina for 5 years on average, and a mean number of weekly attacks of 2.4. Thirteen patients had previous myocardial infarction. Nineteen patients received nifedipine (40 mg per day) then trimetazidine (60 mg per day), and 20 patients received the drugs in the opposite order. Each therapeutic period of 6 weeks was preceded by 1 week of washout with placebo. Drug efficacy was assessed by a bicycle exercise tolerance test, performed at the beginning and at the end of each therapeutic period, and by clinical symptoms observed with placebo or with treatment. The statistical analysis was performed according to a crossover design, with repeated measurements. The decrease of the number of weekly attacks was not significantly different with trimetazidine and nifedipine. Results on the exercise test showed no significant differences for maximum workload, the duration of exercise, ST-segment depression at peak exercise, and the time to 1-mm ST-segment depression. Heart rate and systolic blood pressure were not significantly different at rest and at peak exercise. However, the change in the rate-pressure product at the same workload differed significantly between the drugs: It decreased with nifedipine and remained unchanged with trimetazidine, indicating the difference to be in the mode of action of the drug. In conclusion, trimetazidine was as efficient as nifedipine in stable angina and had a lower incidence of side effects.

Key words

effort angina trimetazidine nifedipine 


  1. 1.
    Mosko Witz RM, Piccini PA, Nacarelli GV, et al. Nifedipine therapy for stable angina pectoris: Preliminary results of effects on angina frequency and treadmill exercise response. Am J Cardiol 1979;44:811–816.Google Scholar
  2. 2.
    Mueller HS, Chahine RA. Interim report of multicentre double-blind, placebo-controlled studies of nifedipine in chronic stable angina. Am J Med 1981;71:645–657.Google Scholar
  3. 3.
    Sellier P. Effets de la trimétazidine sur les paramètres ergométriques dans l'angor d'effort. Etude multicentrique contrôlée à double insu contre placebo. Arch Mal Coeur 1986;9:1331–1336.Google Scholar
  4. 4.
    Passeron J. Efficacy of trimetazidine in stable effort angina. Double-blind study against placebo. Presse Med 1986;15: 1775–1778.Google Scholar
  5. 5.
    Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Intern Pharmacodyn Thér 1987;286:97–110.Google Scholar
  6. 6.
    Renaud JF. Internal pH, Na+ and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988;1:677–686.Google Scholar
  7. 7.
    Cumming GR. The frequency and possible significance of “abnormal exercise ECG patterns in asymptomatic women.” In: Les épreuves d'effort. Paris: Expansion Scientifique 1978:13–43.Google Scholar
  8. 8.
    Winer BJ, Statistical principles in experimental design, New York: McGraw-Hill, 1971.Google Scholar
  9. 9.
    Timour Q, Goupit P, Lang J. Anti-anginal effects of trimetazidine: Mechanisms. Xth International Congress of Pharmacology, Sydney, Australia, August 23–28, 1987, abstracts, p. 648.Google Scholar
  10. 10.
    Sellier P., Maurice. Recherche des effets hémolynamiques de la trimétazidine, en administration unique chez l'homme. Thérapie 1987;42:245–246.Google Scholar
  11. 11.
    Sugimoto J, Nagata M, Fugono R et al. Strophantin-G toxicity and sodium ions. Jpn Circ J 1970;34:725–732.Google Scholar
  12. 12.
    Honoré E, Adamantidis MM, Challice CE, Dupuis BA. Cardioprotection by calcium antagonists, piridoxilate and trimetazidine. IRCS Med Sci 1986;14:938–939.Google Scholar
  13. 13.
    D'Alché P. Electrocardiographical assessment of trimetazidine antiischemic properties. Cardiovasc Drugs Ther 1990, in press.Google Scholar
  14. 14.
    Didier JP, Roux J, Violot D et al. Les effets de la trimétazidine sur le coeur isolé perfusé de rat en hypoxie: Étude hémodynamique et histologique. Gaz Med Fr 1984; 91(Suppl 26):28–34.Google Scholar
  15. 15.
    Harpey C, Labrid C, Baud L, et al. Evidence for antioxidant properties of trimetazidine. Xth International Congress of Pharmacology, Sydney, Australia, August 23–28, 1987, abstracts, p. 649.Google Scholar
  16. 16.
    Brochier M, Demange J, Duelous G, et al. Therapeutic value of a combination of trimetazidine and a calcium antagonist for the treatment of chronic artery disease. Controlled, double-blind study against placebo. Presse Med 1986;15:1783–1787.Google Scholar
  17. 17.
    Michaelides AP, Vysoulis GP, Bonoris PE, et al. Beneficial effects of trimetazidine in patients with stable angina under beta-blockers. Cardiovasc Drugs Ther 1987;1:268.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Sergio Dalla-Volta
    • 1
    • 2
  • Giuseppe Maraglino
    • 1
    • 2
  • Patricia Della-Valentina
    • 1
    • 2
  • Pietro Viena
    • 1
    • 2
  • Alessandro Desideri
    • 1
    • 2
  1. 1.Division of Cardiology, Department of Clinical MedicineUniversity of Padova Medical SchoolItaly
  2. 2.Hospital PadovaItaly

Personalised recommendations